The present invention relates to a method of identifying a subject being susceptible to a co-treatment with an histone deacetylase 10 (HDAC10)-inhibitor, said subject being in need of and/or being treated with cancer therapy against a cancer, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an autophagy-related gene 4D (ATG4D) product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor. Moreover, The present invention relates to a method of predicting the risk of recurrence and/or progression of a cancer in an subject treated by cancer therapy, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an ATG4D product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) predicting the risk of recurrence and/or progression of a cancer treated by cancer therapy. The present invention also relates to a device for identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor, a kit adapted to carry out the method of the present invention. Finally, the invention relates to 2-(4-butoxyphenyl)-N-hydroxyacetamide (bufexamac) for use in treating cancer in a subject, wherein said bufexamac is to be applied in a co-treatment with cancer therapy.La présente invention concerne un procédé didentification dun sujet sensible à un co-traitement avec un inhibiteur dhistone déacétylase 10 (HDAC10), ledit sujet devant être traité et/ou étant traité par une thérapie anticancéreu
